Research programme: neurological disorder therapies - NPS

Drug Profile

Research programme: neurological disorder therapies - NPS

Alternative Names: CSC 500; CSC 500-204; NPS 156; NPS 1897; NPSP 156

Latest Information Update: 24 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NPS Pharmaceuticals
  • Class
  • Mechanism of Action Glycine NMDA-associated agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued CNS disorders; Epilepsy; Neuropathic pain; Schizophrenia

Most Recent Events

  • 16 Oct 2007 Preclinical development is ongoing
  • 08 Nov 2006 Preclinical trials in Neuropathic pain in USA (unspecified route)
  • 31 Oct 2003 Preclinical trials in CNS disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top